ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.31
+0.14 (2.27%)
Dec 16, 2025, 1:55 PM EST - Market open
ImageneBio Revenue
ImageneBio had revenue of $800.00K in the twelve months ending September 30, 2025. In the year 2024, ImageneBio had annual revenue of $3.50M, down -56.04%.
Revenue (ttm)
$800.00K
Revenue Growth
-56.04%
P/S Ratio
82.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
67.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.50M | -4.46M | -56.04% |
| Dec 31, 2023 | 7.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIMA News
- 4 weeks ago - ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - GlobeNewsWire
- 5 weeks ago - ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - GlobeNewsWire
- 4 months ago - ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million - GlobeNewsWire
- 5 months ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire
- 5 months ago - Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewsWire
- 5 months ago - Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals - GlobeNewsWire
- 1 year ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - GlobeNewsWire